Effect of a MUC5AC antibody (NPC-1C) administered with second-line gemcitabine and nab-paclitaxel on the survival of patients with advanced pancreatic ductal adenocarcinoma: A randomized clinical trial

Authors

Brandon M Huffman, Harvard Medical School
Andrea Wang-Gillam, Washington University School of Medicine in St. Louis
et al.

Journal

JAMA Network Open

Publication Date

1-3-2023

Volume

6

Issue

1

First Page

e2249720

Document Type

Open Access Publication

DOI

10.1001/jamanetworkopen.2022.49720

Rights and Permissions

Huffman BM, Basu Mallick A, Horick NK, et al. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(1):e2249720. doi:10.1001/jamanetworkopen.2022.49720. This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2023 Huffman BM et al. JAMA Network Open.

Recommended Citation

Huffman, Brandon M; Wang-Gillam, Andrea; and et al., "Effect of a MUC5AC antibody (NPC-1C) administered with second-line gemcitabine and nab-paclitaxel on the survival of patients with advanced pancreatic ductal adenocarcinoma: A randomized clinical trial." JAMA Network Open. 6, 1. e2249720 (2023).
https://digitalcommons.wustl.edu/oa_4/1127

Additional Links

Supplemental material is available for this article at publisher site.